The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States
J Infect Dis. 2020 Nov 27;222(Supplement_9):S773-S781. doi: 10.1093/infdis/jiaa574.
Stacey B Trooskin 1 2, Gregory Dore 3, Jay Kostman 1
Author information
1Philadelphia FIGHT Community Health Centers, Philadelphia, Pennsylvania, USA.
2Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
3The Kirby Institute, University of New South Wales, Sydney, Australia.
Abstract
The opioid epidemic in the United States, along with a lack of adequate harm reduction services, has contributed to a sharp rise in hepatitis C virus (HCV) infections. Despite considerable evidence of the effectiveness of HCV treatment in people who inject drugs (PWID), and recommendations from clinical guidelines to prioritize treatment in PWID, there are multiple barriers to broad uptake of HCV treatment. These barriers exist at the systems level, as well as at the level of medical providers and patients. Interventions to remove treatment barriers in the United States include harm reduction services, simplifying HCV testing algorithms, improved linkage to HCV care services, and application of new treatment models including colocating services at substance use disorder treatment programs. By following the lead of other countries who have addressed the barriers to HCV treatment, the United States has opportunities to do better in addressing the consequences of the opioid epidemic, including chronic HCV infection.